GB-102 for Wet AMD: A Novel Injectable Formulation that Safely Delivers Active Levels of Sunitinib to the Retina and RPE/Choroid for Over Four Months

Yang Ming; Peterson Ward M.; Yu Yun; Kays Joshua; Cardona Delia; Culp David; Gilger Brian C.; Cleland Jeffrey

首页> 外文期刊>Investigative ophthalmology & visual science >GB-102 for Wet AMD: A Novel Injectable Formulation that Safely Delivers Active Levels of Sunitinib to the Retina and RPE/Choroid for Over Four Months

【24h】

GB-102 for Wet AMD: A Novel Injectable Formulation that Safely Delivers Active Levels of Sunitinib to the Retina and RPE/Choroid for Over Four Months

机译：湿AMD的GB-102：一种新型可注射配方，可将Sunitinib的活性水平安全为视网膜和RPE / Choroid，超过四个月

获取原文

获取原文并翻译 | 示例

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

文献代查 >>

页面导航

著录项
相似文献
相关主题

著录项

来源
《Investigative ophthalmology & visual science》 |2016年第12期|共2页
作者
Yang Ming; Peterson Ward M.; Yu Yun; Kays Joshua; Cardona Delia; Culp David; Gilger Brian C.; Cleland Jeffrey;
展开▼
作者单位

GrayBug Inc Baltimore MD USA;

GrayBug Inc Baltimore MD USA;

GrayBug Inc Baltimore MD USA;

GrayBug Inc Baltimore MD USA;

GrayBug Inc Baltimore MD USA;

Powered Res Res Triangle Pk NC USA;

North Carolina State Univ Clin Sci Raleigh NC USA;

GrayBug Inc Baltimore MD USA;

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类眼科学;
关键词

相似文献

外文文献
专利

1. GB-102 for Wet AMD: A Novel Injectable Formulation that Safely Delivers Active Levels of Sunitinib to the Retina and RPE/Choroid for Over Four Months [J] . Yang Ming, Peterson Ward M., Yu Yun, Investigative ophthalmology & visual science . 2016,第12期

机译：湿AMD的GB-102：一种新型可注射配方，可将Sunitinib的活性水平安全为视网膜和RPE / Choroid，超过四个月
2. Sunitinib-Loaded Injectable Polymer Depot Formulation for Potential Once per Year Treatment of Neovascular Age-related Macular Degeneration (wet AMD) [J] . Yu Yun, Peterson Ward, Yang Ming, Investigative ophthalmology & visual science . 2018,第9期

机译：Sunitinib加载的可注射聚合物仓库配方，每年潜在一次治疗新生血管年龄相关的黄斑变性（湿AMD）
3. Ocular metabolism and melanin binding properties of sunitinib, a dual VEGFR/PDGFR inhibitor, that can safely prolong its efficacy for the treatment of wet AMD [J] . Peterson Ward, Crean Christopher, Lappin Rob, Investigative ophthalmology & visual science . 2017,第8期

机译：OUTINIB，Sunitinib，双VEGFR / PDGFR抑制剂的眼睛代谢和黑色素结合特性，可以安全地延长其对湿AMD处理的疗效
4. VEGF-R2/Caveolin-1 Pathway of Undifferentiated ARPE-19 Retina Cells: A Potential Target as Anti-VEGF-A Therapy in Wet AMD by Resvega an Omega-3/Polyphenol Combination [O] . Flavie Courtaut, Alessandra Scagliarini, Virginie Aires, 2021

机译：未分化的ARPE-19视网膜细胞的VEGF-R2 / Caveolin-1途径：通过RESVAGAω-3 /多酚组合的湿AMD的潜在目标作为抗VEGF-A治疗
5. Efficacy and safety of two new formulations of artificial tears in subjects with dry eye disease: a 3-month, multicenter, active-controlled, randomized trial [O] . Peter Simmons, Haixia Liu, Cindy Carlisle-Wilcox, 2015

机译：两种新的人工泪液在干眼症疾病中的疗效和安全性：3个月，多中心，主动控制，随机试验

GB-102 for Wet AMD: A Novel Injectable Formulation that Safely Delivers Active Levels of Sunitinib to the Retina and RPE/Choroid for Over Four Months

著录项

相似文献

相关主题

期刊订阅